U.S. Addictions Therapeutics Market to Reach USD 29.8 Billion by 2034

Pune, India, November 2025 - According to the latest research by Exactitude Consultancy, the U.S. Addictions Therapeutics Market is projected to grow from USD 14.6 billion in 2024 to USD 29.8 billion by 2034, expanding at a CAGR of 7.2% during the forecast period (2025-2034). The growth is driven by increasing opioid and alcohol dependency rates, government-backed recovery programs, and rapid advancements in neuropharmacology and behavioral therapy integration.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/76072

Key Takeaways
• Market Size 2024: USD 14.6 Billion
• Forecast 2034: USD 29.8 Billion
• CAGR (2025-2034): 7.2%
• Therapy Types: Alcohol Addiction, Opioid Addiction, Tobacco/Nicotine Addiction, Stimulant Addiction, Others
• Key Drivers: Rising Substance Abuse, Biotech R&D Expansion, Federal Support Programs, and Digital Therapeutics Adoption
• Dominant Region: United States (global leader in addiction research & treatment)
• Major Players: Indivior PLC, Alkermes, Pfizer, Johnson & Johnson, Opiant Pharmaceuticals, BioCorRx, Titan Pharmaceuticals, Mallinckrodt Pharmaceuticals, Adial Pharmaceuticals, Pear Therapeutics

Market Story
The U.S. addictions therapeutics market is at a critical turning point, where medical innovation is reshaping traditional recovery frameworks. Driven by the ongoing opioid crisis and a rising number of cases related to alcohol, tobacco, and prescription drug misuse, the demand for pharmacological and behavioral intervention solutions continues to surge.

New drug development, expanding treatment centers, and the adoption of digital behavioral therapy platforms are revolutionizing patient outcomes. Biotech companies are increasingly leveraging AI-assisted molecule screening, CRISPR-based genetic insights, and mobile health applications to enhance treatment personalization and reduce relapse rates.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/76072/us-addictions-therapeutics-market

Segmentation Overview
• By Drug Type:
Alcohol Addiction Treatment Drugs, Nicotine Replacement Therapies (NRTs), Opioid Addiction Medications (Methadone, Buprenorphine, Naltrexone), Others
• By Treatment Type:
Pharmacotherapy, Behavioral Therapy, Combination Therapy
• By Distribution Channel:
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Rehabilitation Centers
• By End User:
Hospitals, Specialty Clinics, Rehab Centers, Research Institutes

Recent Developments
• Indivior PLC: Expanded its portfolio with Sublocade® (extended-release buprenorphine) to improve long-term opioid dependency management.
• Alkermes: Launched Vivitrol® across additional states under Medicaid coverage, boosting treatment accessibility.
• Pfizer & Pear Therapeutics: Collaborated on prescription digital therapeutics (PDTs) integrating behavioral health support apps.
• Titan Pharmaceuticals: Advanced trials for Probuphine®, an implantable formulation ensuring steady medication release.
• Adial Pharmaceuticals: Reported progress on AD04, a serotonin receptor modulator targeting alcohol addiction relapse prevention.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=76072

Expert Insight
"The fight against addiction is entering a scientific renaissance. Combining pharmacological precision with behavioral reinforcement and digital care platforms will transform the U.S. recovery landscape over the next decade," said Anurag Tiwari, Senior Life Sciences Analyst at Exactitude Consultancy.

Market Drivers
1. Surging Opioid Crisis: More than 2.1 million Americans suffer from opioid-related disorders, necessitating broad therapeutic interventions.
2. Government Initiatives: Federal grants under programs like SAMHSA and NIH accelerate adoption of new therapies and rehab frameworks.
3. Innovation in Drug Delivery: Long-acting injectables and implantable systems improve patient adherence and relapse prevention.
4. Rising Acceptance of Digital Therapeutics: FDA-approved mobile and AI-based behavioral therapy tools are redefining home-based recovery.
5. Growing Biotech Pipeline: Several U.S. startups are exploring anti-craving, neuroplasticity-enhancing, and immunotherapy-based drug candidates.

Forecast & Regional Insights
The U.S. dominates the global addiction therapeutics landscape due to high treatment awareness, advanced healthcare systems, and government backing. The ongoing integration of AI, neuroscience, and precision drug delivery is expected to push the boundaries of recovery outcomes.

By 2034, addiction therapy in the U.S. will evolve from symptomatic management toward personalized, data-driven, and hybrid (digital + pharmacological) care models-reshaping national strategies for rehabilitation and mental health.

Conclusion
The U.S. Addictions Therapeutics Market is on a transformative path powered by biotechnology, public health reforms, and digital innovation. As pharma companies and policymakers collaborate to tackle one of America's most persistent health challenges, the decade ahead will mark a decisive shift toward precision-based recovery solutions that combine empathy, science, and technology.

This report is also available in the following languages : Japanese (米国の依存症治療薬市場), Korean (미국 중독 치료 시장), Chinese (美国成瘾治疗市场), French (Marché américain des traitements contre la toxicomanie), German (US-Markt für Suchttherapien), and Italian (Mercato terapeutico delle dipendenze negli Stati Uniti), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/76072

Our More Reports:

Gastrointestinal Therapeutics Market
https://exactitudeconsultancy.com/reports/2915/gastrointestinal-therapeutics-market

Digital Therapeutics (DTx) Market
https://exactitudeconsultancy.com/reports/7904/digital-therapeutics-dtx-market

Biologics Safety Testing Market
https://exactitudeconsultancy.com/reports/28396/biologics-safety-testing-market

Chronic Lymphocytic Leukemia Therapeutics Market
https://exactitudeconsultancy.com/reports/28626/chronic-lymphocytic-leukemia-therapeutics-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.